<DOC>
	<DOCNO>NCT00938119</DOCNO>
	<brief_summary>This multicenter , prospective , observational registry ass efficacy safety outcomes associate percutaneous coronary intervention ( PCI ) implantation CYPHER Select™+ Sirolimus-eluting Coronary Stents Chinese diabetic patient coronary artery disease routine clinical practice .</brief_summary>
	<brief_title>Care China-Diabetes</brief_title>
	<detailed_description>The study objective ass incidence major adverse cardiovascular event ( MACE ; define composite clinically drive target-lesion revascularization , cardiac death , myocardial infarction , stent thrombosis ) 12-month follow-up , stent thrombosis 1-day , 1- 12-month follow-up . Pre-specified analysis perform among patient subpopulation accord level glycemic control ( HbA1c level &lt; 6.5 % &gt; 6.5 % ) ; reference vessel diameter quantitative coronary angiography ( &lt; 2.5 mm &gt; 2.5 mm ) ; stented length ( 8-18 mm ; 23-33 mm ; &gt; 33 mm ) . Quantitative coronary angiographic ( QCA ) analysis perform core lab China Cardiovascular Research Foundation pre- post-index procedure angiograms 12-month follow-up period pre- post-reintervention procedure case clinically-driven PCI revascularization . Also , multivariable analysis conduct investigate potential predictor 12-month MACE rate routine clinical practice . The registry conduct 45 center China , CYPHER Select™+ Sirolimus-eluting Coronary Stent commercially available . Data collect 2,500 diabetic patient treat CYPHER Select™ + Sirolimus-eluting Coronary Stent . Primary outcome : MACE ( clinically drive TLR , cardiac death , MI , ST ) 12 month Secondary outcome : ARC ( probable + definite ) ST 1-day , 1 12 month</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<criteria>Patients age 18 80 ( inclusive ) receive CYPHER SELECT™+ Sirolimuseluting Coronary Stent accord standard clinical practice financially feasible The patient guardian agree study protocol schedule clinical followup , provide informed , write consent , approve appropriate Institutional Review Board/Ethics Committee respective clinical site . Patient diagnosis diabetes diagnose index procedure hospitalization base disease diagnosis criterion Any contraindication follow medication : aspirin , heparin , thienopyridines ( clopidogrel/ticlopidine ) , stainless steel , contrast agent , sirolimus An elective surgical procedure plan would necessitate interruption antiplatelet drug first 6 month post enrollment Cardiogenic shock Terminal illness life expectancy &lt; 1 year STsegment elevation myocardial infarction within 7 day prior index procedure Any patient receive coronary stent ( ) within 1 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Cardiovascular disease</keyword>
	<keyword>Diabetes</keyword>
</DOC>